MedTrace Logo

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

NCT02851745 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2021-05-25

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the effect of linagliptin 5 mg daily versus the corresponding placebo on the LV systolic function (measured by midwall shortening analysis) in patients with T2DM and a documented baseline concentric LV geometry and LV systolic dysfunction.

Conditions

  • Diabetes Mellitus, Type 2
  • Left Ventricular Systolic Dysfunction

Interventions

DRUG

Linagliptin

DRUG

Placebo

Sponsors & Collaborators

  • Fondazione dell'Associazione Medici Diabetologi

    collaborator UNKNOWN

  • Heart Care Foundation

    lead OTHER

Principal Investigators

  • Carlo B. Giorda, MD · Ospedale Maggiore - Diabetologia Malattie Metaboliche - Chieri

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-07-02
Completion
2019-07-02

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02851745 on ClinicalTrials.gov